Last reviewed · How we verify
Ambisome and Paromomycin
Ambisome (liposomal amphotericin B) disrupts fungal cell membranes by binding ergosterol, while paromomycin is an aminoglycoside antibiotic that inhibits protein synthesis in parasites.
Ambisome (liposomal amphotericin B) disrupts fungal cell membranes by binding ergosterol, while paromomycin is an aminoglycoside antibiotic that inhibits protein synthesis in parasites. Used for Visceral leishmaniasis (kala-azar), Fungal infections in immunocompromised patients.
At a glance
| Generic name | Ambisome and Paromomycin |
|---|---|
| Sponsor | Drugs for Neglected Diseases |
| Drug class | Antifungal and antiparasitic combination |
| Target | Fungal ergosterol; parasitic 30S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ambisome is a lipid formulation of amphotericin B that preferentially targets fungal ergosterol in cell membranes, causing membrane disruption and cell death while reducing toxicity to human cells. Paromomycin is an aminoglycoside that binds to the 30S ribosomal subunit of parasites, inhibiting protein synthesis. Together, this combination targets both fungal and parasitic pathogens, particularly in visceral leishmaniasis.
Approved indications
- Visceral leishmaniasis (kala-azar)
- Fungal infections in immunocompromised patients
Common side effects
- Nephrotoxicity
- Infusion-related reactions
- Hypokalemia
- Ototoxicity
- Hepatotoxicity
Key clinical trials
- Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011) (PHASE2)
- Short Course Regimens for Treatment of PKDL (Sudan) (PHASE2)
- Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh (PHASE3)
- Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis (PHASE3)
- Combination Therapy in Indian Visceral Leishmaniasis (PHASE3)
- Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ambisome and Paromomycin CI brief — competitive landscape report
- Ambisome and Paromomycin updates RSS · CI watch RSS
- Drugs for Neglected Diseases portfolio CI